PLUS1
10.98
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ContraFect Corporation | CFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.14 | 1.29% | 10.98 | 10.4573 | 11.94 | 10.90 | 10.84 | 00:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.00 | 11.90 | 7.90 | 66.39% | 5 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,816 | 367,421 | $ 11.22 | $ 4,122,669 | 285,715 | 0.2693 - 12.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 3,706 | $ 10.98 | USD |
ContraFect Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 16.83M | 1.53M | $ -37.68M | -5.10 | 21.70 | 75.03k |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
ContraFect News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/21/2020 | 17:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2020 | 17:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2020 | 17:13 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2020 | 17:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2020 | 17:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/14/2020 | 16:47 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/14/2020 | 16:30 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CFRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.35 | 12.10 | 8.35 | 10.70 | 404,235 | 2.63 | 31.5% |
| 1 Month | 1.13 | 12.10 | 0.72 | 3.37 | 677,002 | 9.85 | 871.68% |
| 3 Months | 0.36 | 12.10 | 0.277 | 1.06 | 1,932,275 | 10.62 | 2,950.0% |
| 6 Months | 0.3855 | 12.10 | 0.2693 | 0.9461356 | 1,035,023 | 10.59 | 2,748.25% |
| 1 Year | 0.4632 | 12.10 | 0.2693 | 0.7560785 | 923,278 | 10.52 | 2,270.47% |
| 3 Years | 2.25 | 12.10 | 0.2693 | 0.9228377 | 453,356 | 8.73 | 388.0% |
| 5 Years | 4.18 | 12.10 | 0.2693 | 1.15 | 295,626 | 6.80 | 162.68% |
ContraFect Description
| ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases. |
